Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Clinical trial NCT04902261 · UNKNOWN

Trial details

NCT number: NCT04902261
Sponsor: Changhai Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Pancreatic Cancer

Start date: 2020-11-20
Primary completion: 2023-11-20
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.